

Elektta to offer improved clinical quality assurance through investment in iRT Systems

STOCKHOLM – Elektta (EKTA-B.ST), announced today that it has purchased a minority stake in the German company, iRT Systems GmbH, in order to improve its quality assurance (QA) offering to clinics and hospitals around the world.

For the past six years, iRT Systems has developed the Integral Quality Monitor (IQM) system in cooperation with Princess Margaret Cancer Centre, part of the University Health Network (UHN), in Toronto, Canada. IQM is the first verification system available on the market that monitors the delivered treatment while comparing it to the planned treatment in real time. IQM is completely integrated into the treatment workflow, acquiring high quality data automatically without user interaction. Leading radiation therapy departments around the world have extensively tested IQM and are implementing IQM in their clinical routine as an integral part of their quality assurance program – and among them are many Elektta customers.

“Elektta relentlessly pursues the advancement of treatment quality assurance – through innovation, collaboration or procurement – by elevating quality control at all stages of the workflow,” said Maurits Wolleswinkel, Head of Portfolio and Chief Strategy Officer at Elektta. “With our stake in iRT, we can help ensure that all oncology departments can do so, more accurately, efficiently and reliably, by using IQM.”

Jürgen Oellig, Managing Director at iRT, said: “By investing in IQM, clinics are investing in the most advanced quality assurance technology, uniquely offering real-time verification during the patient treatment. And by investing in iRT, Elektta will enable its customers to automate all their dosimetric QA processes so they can provide the best possible treatment quality and a new level of safety for their patients.”

IQM has CE mark, FDA 510(k) clearance as well as regulatory approvals in Canada and Australia and other markets.

#

For further information, please contact:

Oskar Bosson, Global EVP Corporate Communications and Investor Relations

Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elektta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager

Tel: +1 770 670 2524, e-mail: raven.canzeri@elektta.com

Time zone: EST: Eastern Standard Time

About Elektta

For almost five decades, Elektta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments.

Headquartered in Stockholm, Sweden, Elektta is listed on NASDAQ Stockholm Exchange.

Visit elektta.com or follow [@Elektta](https://twitter.com/Elektta) on Twitter.